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Behçet's disease (BD) is a genetically complex disease of unknown etiology, characterized
by recurrent inflammatory attacks affecting orogenital mucosa, eyes, and skin. We
performed a GWAS with 311,459 SNPs in 1215 BD patients and 1278 healthy controls from
Turkey. We confirmed the known HLA-B51 association and identified a second,
independent association within the MHC Class I region. We also found one SNP with
genome-wide evidence for association within the gene encoding interleukin-10 (IL10). A
meta-analysis including a total of 2430 cases and 2660 controls established associations with
the IL10 variant (rs1518111, P=3.54×10-18, odds ratio 1.45 with 95% confidence interval
1.34-1.58) and with a variant located between the interleukin-23 receptor (IL23R) and
interleukin 12 receptor β2 (IL12RB2) genes (rs924080, P=6.69×10-9, odds ratio 1.28 with
95% confidence interval 1.18-1.39). The disease-associated IL10 variant (rs1518111 A
allele) was associated with diminished mRNA expression and low protein production,
suggesting novel therapeutic targets for BD.
BD is prevalent in Middle Eastern countries with the highest rate (4 in 1000 individuals)
found in Turkey. A genetic contribution to BD is supported by the high sibling recurrence
risk ratio (λs), estimated from 11.4 to 52.5 in the Turkish population1. HLA-B51 is the most
strongly associated known genetic factor2, however it accounts for less than 20% of the
genetic risk, even in familial cases3, indicating that genetic factors remain to be discovered.
Candidate gene studies and several small GWASs4,5 have examined BD genetics, but the
studies have been generally underpowered, making interpretation and replication of the
results problematic.
We therefore performed a GWAS of 311,459 autosomal SNPs in 1215 BD cases and 1278
healthy controls from Turkey (Fig. 1, Supplementary Fig. 1, and Supplementary Table 1).
Only SNP genotype data that met strict quality control standards (see Online Methods) were
included. A principal components method (Online Methods) was used to evaluate
population stratification in the cases and the controls. After correction for 6 PCs, λGC, a
measure of genomic inflation, was reduced from 1.06 to 1.05 (Supplementary Fig. 2a, b, c).
Correcting for 6 PCs in the absence of the strongly associated MHC region SNPs reduced
λGC from 1.05 to 1.04 (Supplementary Fig. 2d). Given the minimal degree of population
stratification, uncorrected data are presented. P < 5.0 × 10-8 was considered genome-wide
significance.
The most significantly associated SNPs (P value < 10-44) were located on chromosome 6 in
the MHC region. To evaluate the contribution of the HLA-B51 type to BD, we determined
the HLA-B types of 1190 of the cases and 1257 of the controls. Occurrence of the HLA-B51
type (one or two copies) was found in 59.1% of cases and only 29.3% of controls (odds ratio
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= 3.49 [95% CI = 2.95 to 4.12], P = 5.47 × 10-50). Within the HLA-B region the most
significantly associated SNPs were located from telomeric to the HLA-B coding region to
centromeric to MICA (encoding MHC Class I chain related sequence A), which has been
suggested to be the source of the BD-HLA-B51 association6. We found the HLA-B51 type
was more strongly associated with disease than was any genotyped SNP (HLA-B51 allele
frequency = 0.352 in cases and 0.159 in controls, P = 1.44 × 10-54, Fig. 2). Strong linkage
disequilibrium (LD) was observed between HLA-B51 and all the SNPs located from HLA-B
to more than 62 kb centromeric to the MICA gene, despite spanning several blocks of LD
(Supplementary Fig. 3). This LD pattern is observed because the HLA-B51 variant is found
almost exclusively on a single extended haplotype. This extended haplotype occurred at
0.321 frequency in cases and 0.144 frequency in controls. Interestingly, the identical SNP
haplotype, but lacking HLA-B51, occurred in cases and controls equally at 0.04 frequency,
suggesting that HLA-B51 is required for the disease association in the HLA-B region.
We next performed a conditional logistic regression analysis of the 292 SNPs from the
MHC region with allelic Chi-squared P < 0.0001, specifying HLA-B51 as a covariate. None
of the HLA-B/MICA region SNPs remained significantly associated with BD in the
conditional analysis (Fig. 2). After accounting for the effect of HLA-B51, three SNPs within
the HLA-A gene region with disease-associations retained genome-wide significance. The
most strongly associated SNP, rs9260997, located 50 kb centromeric to the HLA-A gene,
had a regressor P value = 5.49 × 10-9, suggesting a highly significant association
independent of the HLA-B51 association. Coincidentally, an association of markers within
the HLA-A region, independent of HLA-B51, was recently described in Japanese BD
patients with attribution of the association to the HLA-A26 allele5.
In the association data (Fig. 1) we identified near genome-wide significance for one non-
MHC SNP, rs936551 (P = 5.29 ×10-8), located at the telomeric end of the short arm of
chromosome 4, within the promoter region of CPLX1, which encodes complexin-1, a
regulator of exocytosis during vesicle membrane fusion. Additionally, one SNP located
within the first intron of the IL10 gene, rs3024490, was strongly suggestive for association
with a P value = 2.22 × 10-7 (Fig. 1). We also identified an additional 66 SNPs from an
additional 49 chromosomal regions with suggestive evidence for disease association, P <
0.0001 (Supplementary Table 2).
To better evaluate genetic associations within the CPLX1 and IL10 gene regions, we
genotyped the same case and control samples for additional SNPs from the regions predicted
by HapMap CEU data to be in LD with the disease-associated SNP. We also fine-mapped
the IL23R/IL12RB2 region, which was identified in an independent GWAS of Behçet's
disease in the Japanese population7 and within which we found three SNPs with p < 0.0001
(Supplementary Table 2).
In the CPLX1 region, the additional genotyped SNPs increased the estimated coverage (at r2
greater than 0.8) of HapMap Phase II SNPs with minor allele frequency greater than 0.05
from 57% to 93%. The most significantly associated SNPs were located in the promoter
region of the gene, although none were more significantly associated than rs936551
(Supplementary Fig. 4).
In the IL10 gene region, we genotyped 27 additional SNPs resulting in coverage of 100% of
the HapMap Phase II SNPs with greater than 5% minor allele frequency in the CEU
samples. Five SNPs were found strongly associated with BD, with one SNP, rs1518111,
with genome-wide significance (P = 1.88 × 10-8, Fig. 3a). The disease-associated SNPs were
located in the promoter region and the first, second, and third introns of the gene
(Supplementary Fig. 5) and all were in strong LD with one another.
Remmers et al. Page 3
Nat Genet. Author manuscript; available in PMC 2011 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In the IL23R/IL12RB2 region we genotyped 11 additional SNPs increasing coverage from
58% to 88% of the HapMap Phase II SNPs with greater than 5% minor allele frequency in
the CEU samples. No SNPs were found with stronger association than rs924080 from the
GWAS analysis (Fig. 3b). We identified a recombination hotspot located in the intergenic
region between IL23R and IL12RB2 (Fig. 3b), which is also seen in the HapMap Caucasian
and Asian populations (data not shown). The BD-associated variants were located on the
IL23R side of the hotspot, suggesting the disease association is more likely to influence
IL23R than IL12RB2. Variants within the IL23R gene have been associated with ankylosing
spondylitis8, psoriasis9, and inflammatory bowel disease10, diseases with some phenotypic
overlap with each other and with BD. Neither of two IL23R coding variants associated with
these seronegative diseases was associated with BD (Fig. 3b).
We genotyped the BD-associated IL10, IL23R/IL12RB2, and CPLX1 SNPs in five
additional collections of BD cases and controls from Turkey, the Middle East, Europe, and
Asia (see Table 1 and Online Methods). A surrogate marker (rs11248047) was used in the
place of the CPLX1 disease-associated SNP (rs936551), which failed quality control in the
replication assay (both markers shown in Supplementary Fig. 4). The results are shown in
Table 1. A number of the UK Caucasian and Middle Eastern Arab samples were previously
tested for association of two IL10 promoter region SNPs with BD. Although an association
with disease was reported in the UK collection, the association had not replicated in the
Middle Eastern Arab collection11. The BD-associated IL10 SNP identified in the Turkish
population, rs1518111, reached statistical significance after correction for three tests (P <
0.017) in the Middle Eastern Arab and Greek collections and was of nominal significance (P
< 0.05) in the UK Caucasian collection (Table 1). For the most part, the IL23R/IL12RB2
and CPLX1 SNPs showed the same trend as found in the Turkish samples; however the
associations did not reach statistical significance in these smaller collections. Association of
these markers was not observed in the small Turkish replication collection. Although this
lack of association could be explained by small sample size, an alternative explanation could
be that the markers are associated with severe disease, as we have noted that disease
manifestations in the replication collection (drawn from a Dermatology clinic) were milder
than in the discovery collection used for the GWAS, which was obtained from a
Rheumatology clinic.
While analyzing these data we learned that another group had also performed a GWAS for
Behçet's disease7. We exchanged data for cross validation purposes and found that the IL10
and the IL23R/IL12RB2 SNP associations were also strongly supported by the data obtained
from the Japanese population, whereas the CPLX1 association was not observed. A meta-
analysis of all the association data (including a total of 2430 BD cases and 2660 controls)
provided strong evidence for associations of the IL10 and IL23R/IL12RB2 loci with BD
(Table 1). Association of the CPLX1 variant failed to replicate in any of the additional
collections and failed to reach genome-wide significant association in a meta-analysis of the
data. Analysis of even larger numbers of replication samples will be required to establish
whether the CPLX1 locus contributes to BD susceptibility.
Several SNP haplotypes of the IL10 gene promoter have been reported to be associated with
regulation of the gene's expression, but the reported allelic effects have been inconsistent
and difficult to reconcile12-14. We therefore tested for a difference in expression of the gene
from the disease-associated haplotype and other haplotypes by measuring allelic imbalance
of the rs1518111 variant in pre-mRNA from monocytes isolated from 8 healthy individuals
heterozygous for the disease-associated allele. In 8 donors, the pre-mRNA transcript with
the rs1518111 A allele was found at reduced levels compared with the G allele. Expression
from the A bearing chromosome was 35% of expression from the G bearing chromosome
(Fig. 4a).
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To assess whether this expression difference was relevant in terms of cytokine production,
we activated mononuclear cells from healthy Turkish donors with lipopolysaccharide (LPS)
and found significantly lower amounts of IL-10 protein in supernatants from donors
homozygous for the rs1518111 A allele compared with individuals with one or two G alleles
(Fig. 4b). We also cultured monocytes from ethnically diverse healthy donors from the
United States and stimulated them with two Toll-like receptor and nucleotide-binding
oligomerization domain containing receptor ligands, the lipoprotein, Pam3Cys and muramyl
dipeptide. Individuals homozygous for the BD-associated rs1518111 A allele produced
significantly less IL-10 than individuals with one or two G alleles (Fig. 4c), whereas no
statistically significant variation was found in TNFα production (data not shown).
Taken together, these data suggest that a genetic predisposition for low IL-10 expression is a
risk factor for BD. There are extensive data in mouse models linking reduction in IL-10 with
inflammation15. Variants in the IL10 gene region have been shown to be associated with
ulcerative colitis (UC)16, type I diabetes17, systemic lupus erythematosus18, and severe
juvenile rheumatoid arthritis (JRA)12, and IL-10 receptor mutations were recently shown to
cause early onset enterocolitis19. Interestingly, the SNP found in the UC, type 1diabetes, and
lupus studies, rs3024505, was not associated with BD (Fig. 3a) and the BD-associated IL10
variants were not associated with these three diseases, suggesting a different IL-10-related
disease mechanism in BD compared with these other diseases. On the other hand, the IL10
association with severe JRA is the same as for BD.
Variants from several candidate genes have been examined for association with BD.
Although no variants within these genes were found with genome-wide significant
association in the Turkish GWAS, 6 of the 12 genes examined contained at least one SNP
with nominal significance (P < 0.05, Supplementary Table 3). A much larger sample
collection will be required to determine whether any of these genes harbor true BD
susceptibility alleles.
In summary, this GWAS provides new insights into the genetic factors that contribute to
BD. It not only supports the association of HLA-B51 as the primary MHC association with
BD, but also reveals another independent MHC Class I association telomeric to the HLA-B
gene. Most importantly, this study demonstrates that common variations in the IL10 gene
and in the vicinity of the IL23R/IL12RB2 genes predispose to BD. Functional analyses
indicate that the disease-associated IL10 variants cause decreased expression of this anti-
inflammatory cytokine, and thereby, possibly in concert with commensal microorganisms20,
result in an inflammation-prone state, thus suggesting a mechanistic hypothesis and possible
therapeutic targets.
Data accession
The genotype data for the 311,459 SNPs in 1215 Behçet's disease cases and 1278 healthy
controls from Turkey have been deposited in the National Institutes of Health database of
genes and phenotypes, dbGaP (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap), accession
number: phs000272.v1.p1
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Refer to Web version on PubMed Central for supplementary material.
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Online Methods
Patients and healthy controls
GWAS samples were collected at the Behçet's Disease Clinic of Istanbul Faculty of
Medicine, Division of Rheumatology, one of the largest centers for BD in Turkey, as
consecutive patients fulfilling the International Study Group Criteria21. Demographic and
clinical characteristics of the patients are given in Supplementary Table 1. Healthy controls
were selected among blood bank donors or healthy volunteers to match by geographic
location the place of birth of the patients (Supplementary Fig. 1). All healthy controls were
questioned for the absence of recurrent oral aphthous ulcers or other BD-related
manifestations, or a family history for BD. All study participants provided written informed
consent, and the study was approved by the Ethics Committee of the Istanbul Faculty of
Medicine.
The replication study samples were from 1) a non-overlapping set of Turkish cases and
controls obtained from the Department of Dermatology Behçet's Disease Clinic of the
Istanbul Faculty of Medicine, 2) a collection of BD cases and controls of Middle Eastern
Arab origin11, 3) a collection of Greek cases and controls22, 4) a collection of UK Caucasian
BD cases and controls11, and 5) a collection of Korean BD cases and controls collected at
Yonsei University College of Medicine in Seoul, South Korea. All cases fulfilled the
International Study Group Criteria.
DNA preparation
Blood samples were collected from all participants and genomic DNA was isolated using the
MagNA Pure Instrument with the MagNA Pure Compact DNA Isolation Kit for 1 ml
volume (Roche, Mannheim, Germany).
Whole genome SNP typing, quality control, and association analysis
All DNA samples were typed using the Infinium assay (Illumina). The first 332 (146 cases
and 186 controls) samples were typed on Human CNV370-Duo v1.0 chips. The remaining
2329 samples (1175 cases and 1150 controls) were typed on Human CNV370-Quad v3.0
chips. Samples with high call rates using Illumina-provided HapMap clusters (greater than
99% on Duo chips and greater than 99.5% on Quad chips) were clustered and these cluster
locations were used to determine the genotypes of all the samples. All 2657 samples (1321
cases and 1336 controls) had > 95% call rate. SNPs used in the analysis were located on the
autosomes, had > 95% call rate, > 1% minor allele frequency, and Hardy Weinberg
equilibrium p-value > 0.00001 determined separately with Duo and Quad chip data. There
were 335,887 autosomal SNPs on the Duo and 334,556 SNPs on the Quad chips. Filtering
removed 9436 SNPs from the Duo and 11,886 SNPs from the Quad chip data. The Duo and
Quad data were merged omitting SNPs not present on both chips (14,970 non-overlapping
SNPs from the Duo and 11,188 from the Quad chips). The merged, autosomal data included
311,482 SNPs. Heterozygosity of X chromosome SNPs was used to predict the sex of the
samples. We removed 19 samples with sex mismatch. PLINK23 was used to identify
samples with genetic relatedness indicating identity (or monozygotic twin) or first, second,
or third degree relatives. Only one of each pair of identical samples was included; if
however the identity could not be confirmed, both samples were removed. Only one of each
pair of first to third degree related samples was included, selecting the sample that was the
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case or the one with the highest call rate. A total of 145 samples were removed for
relatedness. The samples used in the genome-wide association analysis included 1215 cases
and 1278 controls. The SNP genotypes from these 2493 individuals were refiltered using the
same criteria (> 95% call rate, > 1% minor allele frequency, and Hardy-Weinberg
equilibrium > 0.00001) resulting in 311,459 SNPs in the final analysis.
The SNP data were analyzed for SNP association using Sequence Variation Suite 7 (SVS7)
software (Golden Helix, Bozeman, Montana). A principal components analysis method was
used to detect possible stratification present in the cases and the controls. The genomic
inflation factor λGC was 1.06 before correction for the top 6 principal components and 1.05
after correction, and without the MHC region markers was 1.05 without correction and 1.04
with correction for 6 PCs (Supplementary Fig. 2).
Fine map genotyping
Additional SNPs were selected for genotyping in the regions of LD surrounding the disease-
associated SNPs identified by the genome-wide association analysis. We used the Tagger
algorithm in Haploview24 to select SNPs to augment the coverage of the GWAS SNPs to
obtain 100% coverage of the HapMap Phase II SNPs with greater than 5% minor allele
frequency in the CEU HapMap population with pairwise r2 > 0.8. Genotyping of the same
samples used for the GWAS was performed using the Sequenom iPLEX gold method
(Sequenom, San Diego, California). Case and control DNAs were run at the same time and
genotypes determined using Typer 4.0 software (Sequenom). Genotype clusters were edited
from the combined case and control data without knowledge of the case/control status of
individual samples. Of the 30, 13, and 47 SNPs added respectively to the IL10, IL23R, and
CPLX1 regions, 26, 11, and 30 SNPs passed quality control. The concordance rate for SNPs
genotyped on the Illumina chip and Sequenom iPLEX platforms was 99.83%.
Replication sample genotyping
Replication samples were genotyped for rs1518111, rs924080, and rs11248047 with
TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City, California) using the
manufacturer's protocol and recommended quality control measures. Genotype clusters were
edited from the combined case and control data without knowledge of the case/control status
of individual samples.
HLA-B type analysis
HLA-B types were determined from case and control DNA samples using a reverse
sequence-specific oligonucleotide (SSO) method (One Lambda, Canoga Park, California)
and a Bio-Plex 200 suspension array system (BioRad, Hercules, California). Samples were
scored for 0, 1, or 2 HLA-B51 alleles.
Preparation of PBMCs and monocytes from peripheral blood
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by
centrifugation through Ficoll-Hypaque solution (Biocall Separation solution cat: L6115,
BioChrome AG, Berlin, Germany) and washed twice in phosphate buffered saline (PBS).
Cells were resuspended in culture medium at a concentration of 1 × 106 cells per ml. Cells
were cultured in complete RPMI 1640 supplemented with 10% heat inactivated fetal bovine
serum (cat. SH3008803, Thermo Scientific, Waltham, Massachusetts), 2 mM L-glutamine,
penicillin (100 U/mL), streptomycin (100 ug/mL) (cat. 15670-063, Invitrogen) at 37°C in a
humidified atmosphere containing 5% CO2 (Thermo Scientific). Monocytes were obtained
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from PBMCs by negative selection (Monocyte Isolation Kit II; Miltenyi Biotec, Gladbach,
Grmany). The monocytes were washed and cultured at 2.5 × 105 cells per ml in RPMI 1640
containing 5% FBS.
Assay for IL10 allelic imbalance
A genotype assay for rs1518111 (C___8828803_1_, Applied Biosystems, Foster City,
California), an intronic SNP within the IL10 gene, was used in a quantitative expression
assay to compare the relative expression of the disease-associated and the other copy of the
IL10 gene in pre-mRNA from heterozygous carriers of the disease-associated haplotype.
Monocytes were isolated from heterozygous carriers of the IL10 disease-associated
haplotype. Total RNA was treated with DNase I (Invitrogen) prior to synthesis of cDNA,
which was used in the assay for relative expression of the two copies of the gene. The
expression data were analyzed in triplicate and corrected for the detection difference of the
two alleles using genomic DNA from each donor. The relative expression of the disease-
associated allele compared with other alleles was determined using the ΔΔCt method:
Relative expression of the A allele compared with the G allele = 2-ΔΔCt
ΔΔCt = (Avg FAM (A) Ct cDNA – Avg FAM (A) Ct gDNA) - (Avg VIC (G) Ct cDNA –
Avg VIC (G) Ct gDNA).
The significance of the difference in expression of the A allele relative to the G allele was
determined with a Wilcoxon matched pairs signed rank test with P < 0.05 considered
significant.
Assay for IL-10 in supernatants of stimulated PBMCs or monocytes
isolated from peripheral blood
For LPS-stimulated PBMCs, LPS (E. coli, Serotype O26:B6, cat. L-3274, Sigma Aldrich,
St. Louis, Missouri) was added to the cells (1 μg/106 cells) and incubated 24 hours.
Supernatants were collected, and IL-10 concentration was analyzed by enzyme-linked
immunosorbent assay (ELISA) with a commercially available kit according to
manufacturer's protocol (Human IL-10 ELISA Kit, cat. KHC0101, Invitrogen). Absorbance
was measured at 450 nm in a DTX 800 Multimode Detector (Beckman Coulter, Brea,
California). The assay detection limit was 7.8 pg/ml.
For MDP + Pam3Cys-stimulated monocyte experiments, cells were stimulated for 24 hours
with medium, or medium supplemented with MDP (10 μg/ml; Sigma Aldrich) and Pam3Cys
(1 μg/ml; InvivoGen, San Diego, California). Supernatants were collected and
concentrations of IL-10 and TNF-α were measured with the Bio-Plex Pro Human Cytokine
x-plex assay. Data were collected using the Bio-Plex 200 system according to the
manufacturer's protocol (Bio-Rad).
A Mann-Whitney test was used to test for significant differences among genotypes with P <
0.05 considered significant. For LPS-stimulated PBMC, 11 homozygotes for the A allele, 13
heterozygotes, and 14 homozygotes for the G allele were used. For the MDP + Pam3Cys
stimulated monocytes, 11 homozygotes for the A allele, 18 heterozygotes, and 18
homozygotes for the G allele were used.
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Figure 1.
Behçet's disease genome-wide association results. The –log10 P values (allelic Chi-squared
test) for association of 311,459 autosomal SNPs in 1215 BD cases and 1278 controls from
Turkey are shown segregated by chromosome and sorted by genomic position.
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Figure 2.
Analysis of associations within the MHC. The 292 SNPs from the MHC region with allelic
Chi-squared P < 0.0001 are shown before (blue symbols) and after (red symbols)
conditioning for HLA-B51. Blue symbols represent -log10 P (allelic Chi-squared test). Red
symbols represent –log10 regressor P-values of the same markers from a logistic regression
analysis with HLA-B51 specified as a covariate. The green horizontal line at –log10P =
7.301 corresponds to the genome-wide significance threshold of 5 × 10-8. The locations of
HLA genes are shown above the association graph.
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Figure 3.
Fine-mapping of the IL10 and IL23R/IL12RB2 regions. Regional association plot and
linkage disequilibrium structure of the disease-associated regions surrounding (a) IL10 and
(b) IL23R/IL12RB2 showing SNPs genotyped in the genome-wide analysis (blue) and fine-
mapping analysis (green). The LD structure of the same regions are shown with red filled
squares linking pairs of markers indicating the intensity of LD by intensity of fill, D’= 1
(intense red) to D’ = 0 (no fill). In (a) the pink circles represent rs1518111 and the yellow
circles represent rs3024505, which is associated with IBD and SLE. In (b) the pink circles
represent rs924080 and the yellow circles represent the IL23R coding variants associated
with other seronegative diseases.
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Figure 4.
Expression analysis of IL10. (a) Allelic imbalance detected by real time PCR of the IL10
SNP, rs1518111 (A is the BD-associated allele), in pre-mRNA from purified monocytes
from healthy, rs1518111 heterozygous blood donors (n=8, p<0.01). The error bar represents
the standard deviation. (b) IL-10 production by peripheral blood mononuclear cells isolated
from healthy Turkish blood donors measured 24 hr after stimulation with LPS, relative to
rs1518111 genotype. (c) IL-10 production by CD14+ monocytes isolated from ethnically
diverse, healthy American blood donors measured 24 hr after stimulation with MDP +
PAM3Cys, relative to rs1518111 genotype. In (b) and (c) the horizontal lines indicate the
medians.
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